2nd Generation, ColoSTAT Multiplex Alpha Kit Outperforms
Filed with ASX · · 3 pages · English
Summary by 6ix AI
Rhythm Biosciences Limited has announced the performance evaluation results of its second-generation ColoSTAT® Multiplex Alpha Kit, which shows superior analytical results compared to the original kit. The preliminary testing involved patient serum samples and demonstrated a statistically significant classification of samples as either cancer or non-cancer. The company plans to work with its contract manufacturing organization to develop the Beta version of the assay for commercial validation.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Rhythm Biosciences Limited on 6ix
Earlier from Rhythm Biosciences
- Board Renewal / Composition Update
- Platform Expansion - Gastric Cancer Diagnostic Test Update
- Product and Market Update - Phase 2 Milestone
- Jun 24 Quarterly Activities Report and Appendix 4C
- Mar24 Quarterly Activities Report and Appendix 4C
Later from Rhythm Biosciences
- Receipt of Research & Development Tax Incentive
- Strong Demand in Share Placement to Raise $3.5 million
- Market Update - All End of CY24 Milestones Attained
- Pause in Trading
- RHY Acquires Genetype Genetic Risk Assessment Business
Follow Rhythm Biosciences into a list and get an email when it puts out news.
Follow Rhythm Biosciences